|Dr. Gary L. Wilcox||Co-Founder, Vice Chairman & Interim CEO||N/A||N/A||1947|
|Dr. Sam Lee||Co-Founder & Pres||N/A||N/A||1960|
|Mr. James J. Martin CPA, CPA, MBA||CFO & Sec.||199.56k||N/A||1967|
|Dr. Roger D. Kornberg||Co-Founder, Chairman of Scientific Advisory Board & Chief Scientist||N/A||N/A||1947|
|Dr. Luz Pascual||VP of Clinical Devel.||N/A||N/A||N/A|
Cocrystal Pharma, Inc., a clinical stage biotechnology company, engages in discovering and developing various novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. It employs structure-based technologies to create antiviral drugs. The company's products include CC-31244, a Phase IIa ready broad-spectrum novel non-nucleoside replication inhibitor for the treatment of hepatitis C virus; and CC-42344, a novel PB2 inhibitor that is in preclinical development trials for the treatment of influenza. It also has a pipeline of products that are in early preclinical programs. The company has collaborations with Emory University; University of Pittsburgh; and NIH. Cocrystal Pharma, Inc. was founded in 2007 and is headquartered in Tucker, Georgia.
Cocrystal Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.